TRML Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of -- compared to Tourmaline Bio's net margin of --. Tourmaline Bio's return on equity of -- beat CEL-SCI's return on equity of --.

Tourmaline Bio has a consensus price target of $58.33, signalling upside risk potential of 167.75%. On the other hand CEL-SCI has an analysts' consensus of -- which suggests that it could grow by 1004.76%. Given that CEL-SCI has higher upside potential than Tourmaline Bio, analysts believe CEL-SCI is more attractive than Tourmaline Bio.

Tourmaline Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.593, suggesting its less volatile than the S&P 500 by 40.711%.

Tourmaline Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tourmaline Bio pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Tourmaline Bio quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Tourmaline Bio's net income of -$20.2M is lower than CEL-SCI's net income of -$6.9M. Notably, Tourmaline Bio's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tourmaline Bio is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of -- compared to Tourmaline Bio's net margin of -416.75%. Tourmaline Bio's return on equity of -- beat IGC Pharma's return on equity of -137.43%.

Tourmaline Bio has a consensus price target of $58.33, signalling upside risk potential of 167.75%. On the other hand IGC Pharma has an analysts' consensus of -- which suggests that it could grow by 914.89%. Given that IGC Pharma has higher upside potential than Tourmaline Bio, analysts believe IGC Pharma is more attractive than Tourmaline Bio.

Tourmaline Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.288, suggesting its more volatile than the S&P 500 by 28.8%.

Tourmaline Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tourmaline Bio pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

Tourmaline Bio quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $412K. Tourmaline Bio's net income of -$20.2M is lower than IGC Pharma's net income of -$1.7M. Notably, Tourmaline Bio's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tourmaline Bio is -- versus 21.61x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Tourmaline Bio's net margin of -49.65%. Tourmaline Bio's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Tourmaline Bio has a consensus price target of $58.33, signalling upside risk potential of 167.75%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 589.94%. Given that NovaBay Pharmaceuticals has higher upside potential than Tourmaline Bio, analysts believe NovaBay Pharmaceuticals is more attractive than Tourmaline Bio.

Tourmaline Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Tourmaline Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tourmaline Bio pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Tourmaline Bio quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Tourmaline Bio's net income of -$20.2M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Tourmaline Bio's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tourmaline Bio is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Tourmaline Bio's net margin of 18.02%. Tourmaline Bio's return on equity of -- beat Protalix BioTherapeutics's return on equity of -29.54%.

Tourmaline Bio has a consensus price target of $58.33, signalling upside risk potential of 167.75%. On the other hand Protalix BioTherapeutics has an analysts' consensus of -- which suggests that it could grow by 686.52%. Given that Protalix BioTherapeutics has higher upside potential than Tourmaline Bio, analysts believe Protalix BioTherapeutics is more attractive than Tourmaline Bio.

Tourmaline Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.741, suggesting its less volatile than the S&P 500 by 25.895%.

Tourmaline Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tourmaline Bio pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Tourmaline Bio quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18M. Tourmaline Bio's net income of -$20.2M is lower than Protalix BioTherapeutics's net income of $3.2M. Notably, Tourmaline Bio's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 115.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tourmaline Bio is -- versus 3.06x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.